Clinical trial Recruiting at 1 site Observational Ages 18 and up Women only

New tool for uterine sampling to detect gynecological cancers

Official title: DOvEEgene Fleur: New Uterine Sampling Tool

Run by McGill University · NCT04258449 · Data updated 2026-11-12

This study is testing a new tool to see if it can help find signs of gynecological cancers in women who are having surgery for tumors by looking for cancer DNA in samples taken from the uterus.

Quick facts

Study typeObservational
Ages18 Years and up
SexWomen only
Enrollment40 (estimated)
SponsorMcGill University
Academic / other
Locations1 site (Montreal, Quebec)
StatusRecruiting
StartedDecember 11, 2020
Main results expectedOctober 1, 2026
Study endsOctober 1, 2026
Registry record updatedSeptember 26, 2025
Trial IDNCT04258449 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women aged 18 and older with suspected or confirmed cancer of the upper genital tract who are scheduled for surgery.

Probably not a fit

Patients who have had a prior hysterectomy or are pregnant may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop and validate a novel molecular test called DOvEEgene, which focuses on early diagnosis of endometrial, tubal, and ovarian cancers by identifying cancer-specific mutations in pap samples taken from the uterus. The study builds on previous research and seeks to improve patient tolerability during sampling by using a new uterine sampling tool. Participants will include women with suspected or confirmed gynecological diseases who are undergoing surgery for tumor removal. The study will assess the effectiveness of this new tool in detecting cancer DNA amidst a challenging background of benign conditions.

Why it matters

Potential benefit: If successful, this study could lead to earlier and more accurate detection of gynecological cancers, improving patient outcomes.

How similar studies have gone: Previous studies have shown promise in using molecular tests for cancer detection, making this approach a continuation of established research.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Be at least 18 years of age.
* Have capacity to understand the study.
* Be able to provide informed consent.
* If the patient has a recently treated cervical abnormality, she must have had a Pap smear with normal results at least 4 months following treatment by loop electrosurgical excision procedure (LEEP) or cone biopsy.
* Have suspected or confirmed cancer of the upper genital tract and be undergoing surgery for said tumor removal.

Exclusion Criteria:

* Prior hysterectomy.
* Be pregnant or possibly pregnant.
* Be nursing, as the device contains phthalates (plasticizers) that "have not been fully characterized and there may be concern for reproductive and developmental effects".
* Have an infected or inflamed cervix.
* Have a confirmed or suspected pelvic infection.
* Have a confirmed or suspected vaginal infection.
* Have had recent history of uterine perforation.
* Patients with recently treated cervical abnormalities must have a Pap smear with normal results at least 4 months following treatment by loop electrosurgical excision procedure (LEEP) or cone biopsy in order to be eligible.

Where it's running

  • Royal Victoria Hospital (Glen Site)
    Montreal, Quebec, Canada
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.